The Ulcerative Colitis Market in Asia Pacific is valued at USD 0.92 billion in 2021 and is projected to grow at a CAGR of 7.9%, to reach USD 1.34 billion by 2026 during the forecast period 2021 to 2026.
The rising prevalence of ulcerative colitis disease, which affects a large number of people, is driving the expansion of the APAC ulcerative colitis market. One of the major factors regulating the industry is the advent of biosimilar. Biosimilars should be less expensive than biologics, making them more affordable in this country. One of the factors driving the emergence of new biosimilar is the projected patent expiration of some drugs.
The industry is estimated to exhibit as key businesses become more involved in product development connected to the field. Pfizer Inc., for instance, started a phase III clinical trial in June 2021 to evaluate tofacitinib's effectiveness, safety, and pharmacokinetics (PK) in pediatric patients with moderately to severely active Ulcerative Colitis. In 2028, the experiment is expected to be completed. Takeda Pharmaceutical Company Limited began a phase III research trial in Japan in June 2021 to evaluate the efficacy and safety of intravenous (IV) Vedolizumab in Japanese patients with moderate to severe Ulcerative Colitis.
The number of patients diagnosed with inflammatory bowel disease (IBD) over the age of 65 is increasing. This is attributable to the increased prevalence of inflammatory bowel disease and an ageing population. In geriatric and adult individuals with ulcerative colitis, the symptoms and behavior are comparable. The aged, on the other hand, are more vulnerable due to comorbidities, higher infection risk, and disease-related consequences. Furthermore, significant R&D and investment by key players in the production of new medicines for UC therapy, as well as an increase in government and non-government organizations funding biologics research, are fueling market expansion.
The market is restrained by the expiration of medication patents and strict government restrictions governing biosimilar approval. Over the forecast period, factors such as high levels of unmet clinical need in ulcerative colitis (UC) and medication side effects are likely to stymie market expansion.
This research report on the APAC Ulcerative Colitis Market has been segmented and sub-segmented into the following categories:
By Product:
By Type:
By Route Of Administration:
By Country:
Due to the presence of major companies and the rising prevalence of Ulcerative Colitis in the area, as well as continued investment for the development of new therapies for the treatment of the ailment, Asia Pacific is likely to lead the ulcerative colitis market.
India’s high frequency of ulcerative colitis disease fuels the ulcerative colitis market's growth. Furthermore, the country's market growth is being fueled by improvements in infrastructure and the rise of the drug development sector. Furthermore, a strong government initiative aimed at improving healthcare facilities via favorable insurance plans.
China, India, and Japan are the three largest contributors to the market. The expanding healthcare infrastructure in these countries is mostly related to significant government spending in the healthcare sector. Rapid urbanization and changing eating habits are also expected to boost the industry in the Asia pacific region significantly. Because of its established healthcare industry and growing awareness of IBD, Japan has a significant portion of the Asia-Pacific Ulcerative Colitis market.
The Top companies leading in the APAC Ulcerative Colitis Market profiled in the report are Abbott Laboratories, GlaxoSmithKline, Pfizer, Takeda Pharmaceuticals, AbbVie, Johnson and Johnson, Merck, Sanofi, F. Hoffmann-La Roche and Shire Pharmaceuticals.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product
5.1.1 Introduction
5.1.2 Monoclonal Antibodies
5.1.2.1 Humira
5.1.2.2 Simponi
5.1.2.3 Remicade
5.1.2.4 Entyvio
5.1.3 Biosimilars
5.1.4 Pharmaceuticals
5.1.4.1 Mesalamine
5.1.4.1.1 Asacol HD
5.1.4.1.2 Pentasa
5.1.4.1.3 Lialda
5.1.4.1.4 sfRowasa
5.1.4.2 Balsazide
5.1.4.2.1 Colazal
5.1.4.2.2 Giazo
5.1.4.3 Budesonide
5.1.5 Y-o-Y Growth Analysis, By Product
5.1.6 Market Attractiveness Analysis, By Product
5.1.7 Market Share Analysis, By Product
5.2 Type
5.2.1 Introduction
5.2.2 Proctosigmoiditis
5.2.3 Ulcerative Proctitis
5.2.4 Pancolitis
5.2.5 Left-sided Colitis
5.2.5 Y-o-Y Growth Analysis, By Type
5.2.6 Market Attractiveness Analysis, By Type
5.2.7 Market Share Analysis, By Type
5.3 Route of Administration
5.3.1 Introduction
5.3.2 Oral
5.3.3 Injectable
5.3.4 Y-o-Y Growth Analysis, By Route of Administration
5.3.5 Market Attractiveness Analysis, By Route of Administration
5.3.6 Market Share Analysis, By Route of Administration
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product
6.1.3.3 By Type
6.1.3.4 By Route of Administration
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product
6.1.4.3 By Type
6.1.4.4 By Route of Administration
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product
6.1.5.3 By Type
6.1.5.4 By Route of Administration
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Abbott Laboratories
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 GlaxoSmithKline
8.3 Pfizer
8.4 Takeda Pharmaceuticals
8.5 AbbVie
8.6 Johnson and Johnson
8.7 Merck
8.8 Sanofi
8.9 F. Hoffmann-La Roche
8.10 Shire Pharmaceuticals
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Apr 2021
